Revision as of 04:14, 26 October 2024 edit76.174.0.57 (talk) Fix.← Previous edit | Latest revision as of 04:14, 26 October 2024 edit undo76.174.0.57 (talk) Tweaks. | ||
Line 61: | Line 61: | ||
Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs.<ref>{{cite book | veditors = Craig CR, Stitzel RE |title=Modern Pharmacology with Clinical Applications |date=2004 |publisher=Lippincott Williams & Wilkins |isbn=978-0-7817-3762-3 }}{{pn|date=January 2021}}</ref> | Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs.<ref>{{cite book | veditors = Craig CR, Stitzel RE |title=Modern Pharmacology with Clinical Applications |date=2004 |publisher=Lippincott Williams & Wilkins |isbn=978-0-7817-3762-3 }}{{pn|date=January 2021}}</ref> | ||
Oxotremorine also produces antipsychotic effects.<ref>{{cite journal | vauthors = Maehara S, Hikichi H, Satow A, Okuda S, Ohta H | title = Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia | journal = Pharmacology, Biochemistry, and Behavior | volume = 91 | issue = 1 | pages = 140–9 | date = November 2008 | pmid = 18651995 | doi = 10.1016/j.pbb.2008.06.023 | s2cid = 12225821 | id = {{INIST|20678587}} }}</ref> | Oxotremorine also produces ]-like effects.<ref>{{cite journal | vauthors = Maehara S, Hikichi H, Satow A, Okuda S, Ohta H | title = Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia | journal = Pharmacology, Biochemistry, and Behavior | volume = 91 | issue = 1 | pages = 140–9 | date = November 2008 | pmid = 18651995 | doi = 10.1016/j.pbb.2008.06.023 | s2cid = 12225821 | id = {{INIST|20678587}} }}</ref> | ||
⚫ | == References == | ||
⚫ | {{Reflist}} | ||
== See also == | == See also == | ||
* ] | * ] | ||
⚫ | == References == | ||
⚫ | {{Reflist}} | ||
{{Muscarinic acetylcholine receptor modulators}} | {{Muscarinic acetylcholine receptor modulators}} |
Latest revision as of 04:14, 26 October 2024
Chemical compound Pharmaceutical compoundClinical data | |
---|---|
Pregnancy category |
|
Routes of administration | Oral, intravenous |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.662 |
Chemical and physical data | |
Formula | C12H18N2O |
Molar mass | 206.289 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Oxotremorine is a drug that acts as a selective muscarinic acetylcholine receptor agonist.
Oxotremorine produces ataxia, tremor and spasticity, similar to those symptoms seen in Parkinsonism, and has thus become a research tool in experimental studies aimed at determining more effective anti-Parkinsonian drugs.
Oxotremorine also produces antipsychotic-like effects.
See also
References
- Tang C, Castoldi AF, Costa LG (April 1993). "Effects of the muscarinic agonist oxotremorine on membrane fluidity in rat lymphocytes". Biochemistry and Molecular Biology International. 29 (6): 1047–54. PMID 8330013. INIST 4025194.
- Craig CR, Stitzel RE, eds. (2004). Modern Pharmacology with Clinical Applications. Lippincott Williams & Wilkins. ISBN 978-0-7817-3762-3.
- Maehara S, Hikichi H, Satow A, Okuda S, Ohta H (November 2008). "Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia". Pharmacology, Biochemistry, and Behavior. 91 (1): 140–9. doi:10.1016/j.pbb.2008.06.023. PMID 18651995. S2CID 12225821. INIST 20678587.
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |